Skip navigation Consumer Fund Healthcare Info & Comm Technology Internet & Digital Media

Predictive Biosciences

Predictive Biosciences is developing proprietary biomarker and assay technology for highly accurate, patient-friendly, real-time cancer diagnostics. The company is focused on validating and demonstrating the superior clinical utility of its protein biomarkers and developing products for commercialization across multiple cancer types. Predictive Biosciences was co-founded in 2006 by Marsha A. Moses, Ph.D., Bruce R. Zetter, Ph.D. and Eugene Chiu.

Recent News

Predictive Biosciences Closes $25 Million Series C Financing

Diagnostic Industry Veteran Kim Blickenstaff Joins Predictive Biosciences’ Board of Directors

Predictive Biosciences Announces Acquisition of OncoDiagnostic Laboratory

Predictive Biosciences’ Breast Cancer Biomarker Findings Highlighted in Proceedings of the National Academy of Sciences

Predictive Biosciences Closes $21.75 Million in Series B Financing

Predictive Biosciences Expands Executive Leadership Team with Two Diagnostic Industry Veteran Appointments

Predictive Biosciences Appoints Life Sciences Industry Veteran Peter Klemm, Ph.D., as Company’s First President and CEO